How integrated CRDMOs streamline drug development

End-to-end drug development works best when discovery, CMC, quality, and manufacturing move together instead of through disconnected handoffs. WuXi AppTec’s integrated CRDMO model is positioned around that idea, with examples showing how coordinated work can shorten timelines for small molecules and TIDES.

Why it matters: - End-to-end drug development can lose time when research, development, quality, and manufacturing are split across separate providers. - An integrated CRDMO can keep decisions, materials, analytical methods, and technical knowledge connected as a program moves forward. - That matters most for complex programs, compressed timelines, and workstreams that must advance in parallel. - The approach is especially relevant for small molecules and TIDES when early technical choices affect downstream CMC and manufacturing work.

What happened: - WuXi AppTec outlined an integrated CRDMO model that connects research, development, and manufacturing across the development pathway. - The company framed integration as more than broad service coverage, saying the key test is whether teams and technical work remain connected as a molecule progresses. - WuXi TIDES was presented as an example of broad capability across discovery synthesis, process development, manufacturing, formulation, packaging, labeling, and distribution. - WuXi AppTec's One Global Quality System was cited as a standardized quality framework across sites. - WuXi AppTec's global network has grown from a single lab to more than 20 sites worldwide.

The details: - CROs primarily support research and development activities. - CDMOs primarily support development and manufacturing activities. - CRDMOs connect research, development, and manufacturing within one operating model. - Breadth means having capabilities across multiple stages, including scientific, analytical, formulation, and manufacturing work. - Integration means those functions operate as one development program rather than isolated service lines. - Quality creates shared expectations across sites through standardized GMP procedures, computerized systems, and training. - Capacity depends on infrastructure, technology, and talent that match program needs over time. - For small molecules, challenging synthetic routes, lower solubility, weaker permeability, or difficult formulation requirements can affect later development stages. - For TIDES, peptides, oligonucleotides, and related synthetic conjugates can require specialized purification and analytical methods, along with different degradation behavior and PK/PD patterns. - Handoffs can create delay when a new team must re-establish materials, analytical methods, documentation, or quality expectations before moving ahead. - API-to-formulation transfer is one common friction point. - In a fragmented model, one provider may make the API while another handles drug-product formulation. - In an integrated framework, API and formulation work can be planned together earlier. - The article said API analytical methods can often be adapted for drug-product work under a unified quality system. - Representative API material can also be prepared in advance for formulation process development where appropriate. - In that example, continuity between API development and formulation saved one to two months, and in some cases more. - The timing benefit was presented as program-specific, not universal.

Between the lines: - The article argues that service menus matter less than operating design. - The real advantage comes from reducing friction between teams that otherwise would have to repeat work or rebuild context. - The strongest case for integration appears when multiple technical risks move together, not when a program is simple or fully linear. - The examples are meant to show how parallel work can protect timelines when a molecule, process, and supply chain are all still evolving.

What's next: - Drug developers will keep weighing CRO, CDMO, and CRDMO models based on how much coordination their programs require. - Programs with complex molecules, unstable supply, or tight IND timelines are likely to be the clearest fit for integrated planning. - Future value will depend on whether a provider can keep quality, materials, analytical work, and manufacturing aligned as projects advance. - The peptide case example showed that parallel execution can support an IND filing deadline, with the submission landing one month early and the program later moving into Phase 2. - The article cautions that each program will still need its own development strategy based on molecule, modality, and risk profile.